NASDAQ: NMRANeumora Therapeutics Inc Stock
$0.66+0.01 (+1.54%)
Updated Apr 21, 2025
NMRA Price
$0.66
Fair Value Price
$0.88
Market Cap
$106.91M
52 Week Low
$0.62
52 Week High
$17.19
P/E
-0.43x
P/B
0.37x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$243.79M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
0.1
Operating Cash Flow
-$183M
Beta
1.25
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
NMRA Overview
Neumora Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases. The company develops navacaprant (NMRA-140), a novel once-daily oral kappa opioid receptor antagonist, which is in phase 3 clinical trials for the treatment of major depressive disorder. It also develops NMRA-511 that is in phase 1 clinical trials in patients with agitation associated with dementia due to Alzheimer's disease; and NMRA-266, which is in the phase 1 clinical trial for the treatment of schizophrenia and other neuropsychiatric disorders. In addition, its preclinical phase product includes NMRA-NMDA for the treatment of schizophrenia; NMRA-CK1d, a CK1d inhibitor program for the treatment of amyotrophic lateral sclerosis; NMRA-NLRP3 for the treatment of certain neurodegenerative conditions; and NMRA-GCase for the treatment of Parkinson's disease. The company was formerly known as RBNC Therapeutics, Inc. and changed its name to Neumora Therapeutics, Inc. in October 2021. Neumora Therapeutics, Inc. was incorporated in 2019 and is headquartered in Watertown, Massachusetts.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine NMRA's potential to beat the market
FStrong Sell
- Stocks with a Zen Rating of Strong Sell (F) had an average loss of -8.02% per year. Learn More
Zen Rating Component Grades
C
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
NMRA
Ranked#409 of 462
Ranked#409 of 462
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $2.55 | A | |
| $7.66 | A | |
| $22.02 | A |
Be the first to know about important NMRA news, forecast changes, insider trades & much more!
NMRA News
Overview
Due Diligence Score
–
Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how NMRA scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
NMRA ($0.66) is undervalued by 25.02% relative to our estimate of its Fair Value price of $0.88 based on Discounted Cash Flow (DCF) modelling, but does not have a significant margin of safety
Below Fair Value Valuation
NMRA ($0.66) is significantly undervalued by 25.02% relative to our estimate of its Fair Value price of $0.88 based on Discounted Cash Flow (DCF) modelling, which includes a healthy margin of safety
Significantly Below Fair Value Valuation
NMRA is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more NMRA due diligence checks available for Premium users.
Valuation
NMRA fair value
Fair Value of NMRA stock based on Discounted Cash Flow (DCF)
Price
$0.66
Fair Value
$0.88
Undervalued by
25.02%
NMRA ($0.66) is undervalued by... subscribe to Premium to read more.
Below Fair Value Valuation
NMRA ($0.66) is significantly undervalued... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
NMRA is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
NMRA price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-0.43x
Industry
-184.27x
Market
27.14x
NMRA price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
0.37x
Industry
4.04x
NMRA is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
NMRA's financial health
Profit margin
Revenue
$0.0
Net Income
-$58.8M
Profit Margin
0%
NMRA's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$317.0M
Liabilities
$29.9M
Debt to equity
0.1
NMRA's short-term assets ($314.06M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
NMRA's short-term assets ($314.06M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
NMRA's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$50.3M
Investing
-$98.8M
Financing
$15.6M
NMRA's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
NMRA vs Biotech Stocks
Neumora Therapeutics Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.